Rituximab for the treatment of follicular lymphoma
National Institute for Health and Clinical Excellence
Record ID 32006000958
English
Authors' objectives:
The aim of this review is to provide guidance on the use of rituximab for the treatment of follicular lymphoma.
Authors' recommendations:
Guidance
Rituximab within its licensed indication (that is, in combination with cyclophosphamide, vincristine and prednisolone) is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/page.aspx?o=TA110
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Antibodies, Monoclonal
- Antineoplastic Agents
- Cyclophosphamide
- Lymphoma, Follicular
- Prednisolone
- Vincristine
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.